Samsung Biologics U.S. expansion is gaining momentum through a landmark acquisition of Human Genome Sciences from GSK, a move that marks its first biomanufacturing presence in the United States.
In a deal valued at USD 280 million, Samsung Biologics America, a wholly owned subsidiary of Samsung Biologics, has entered into a definitive agreement to acquire the Rockville, Maryland-based site from GlaxoSmithKline (GSK). The site, a prominent part of one of the U.S.’s key biopharma clusters, houses two cGMP manufacturing plants with a total drug substance capacity of 60,000 litres.
Strengthening Global Capacity through U.S. Integration
Samsung Biologics U.S. expansion strengthens its global network, bringing total biomanufacturing capacity to 785,000 litres across five sites. The Rockville facility will support both clinical and commercial biologic production, enhancing supply chain resilience for critical therapies in the American market.
To ensure operational continuity, Samsung Biologics will retain more than 500 skilled employees at the site. Further investments are planned to expand production capacity and upgrade technologies, ensuring the facility remains at the forefront of biologics manufacturing.
Strategic Commitment to the U.S. Market
John Rim, CEO and President of Samsung Biologics, stated that the acquisition aligns with the company’s mission to deliver biopharmaceutical innovation globally. He emphasised the importance of deepening collaboration with U.S. federal, state, and local stakeholders to bolster national healthcare infrastructure.
“This acquisition solidifies our presence in the U.S. and reflects our dedication to reliable, scalable manufacturing of life-saving therapeutics,” said Rim.
GSK’s Portfolio Optimisation Continues
For GSK, the divestiture supports its broader strategy to enhance agility across its global manufacturing network. According to Regis Simard, President of Global Supply Chain, the transaction ensures continued U.S.-based production of key medicines while enabling GSK to focus on delivering next-generation vaccines and specialty drugs.
This move complements GSK’s announced $30 billion R&D and manufacturing investment in the U.S. over the next five years, demonstrating its ongoing commitment to strengthening domestic capabilities.
Operational Excellence and Future Vision
Samsung Biologics has consistently demonstrated project delivery excellence, as evidenced by the rapid development of Bio Campus I and II. The company recently secured land for Bio Campus III, intended to house advanced research and manufacturing programmes, including next-generation modalities such as antibody-drug conjugates, mRNA, and organoid-based therapies.
By incorporating the Rockville facility into its global footprint, Samsung Biologics offers its clients flexible, dual-continent production options—reinforcing the reliability and accessibility of essential biologic medicines for U.S. patients.
